(Reuters) – The U.S. government agreed to pay drugmaker Pfizer Inc nearly $2 billion for an additional 3.7 million courses of its COVID-19 antiviral drug Paxlovid, the company said on Tuesday.
The new courses of the drug supplement the 20 million courses previously contracted by Pfizer and are planned for delivery by early 2023, Pfizer said in a statement.
(Reporting by Michael Erman; Editing by Leslie Adler)
